$CYRX
Cryoport, Inc. Stock $cyrx

$cyrx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000155837024003128 Filed on March 13, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$54.59M	$57.26M	$233.3M
YoY Change	-13.09%	-5.13%	-1.7%
Cost Of Revenue	$32.82M	$34.00M	$133.9M
YoY Change	-8.19%	-0.24%	0.39%
Gross Profit	$21.78M	$23.26M	$99.33M
YoY Change	-19.57%	-11.48%	-4.37%
Gross Profit Margin	39.89%	40.62%	42.59%
Selling, General & Admin	$38.30M	$38.81M	$146.9M
YoY Change	15.23%	18.93%	22.34%
% of Gross Profit	175.91%	166.86%	147.87%
Research & Development	$4.752M	$4.749M	$18.04M
YoY Change	22.6%	1.54%	14.74%
% of Gross Profit	21.82%	20.42%	18.16%
Depreciation & Amortization	$7.469M	$7.449M	$27.49M
YoY Change	16.63%	21.44%	20.74%
% of Gross Profit	34.3%	32.02%	27.67%
Operating Expenses	$43.06M	$43.56M	$214.5M
YoY Change	16.0%	16.75%	57.97%
Operating Profit	-$21.28M	-$20.30M	-$115.2M
YoY Change	111.86%	83.98%	260.95%
Interest Expense	$1.338M	$1.309M	$5.503M
YoY Change	-11.33%	7.21%	-10.4%
% of Operating Profit
Other Income/Expense, Net	$2.601M	$4.814M	$15.81M
YoY Change	-47.59%	159.51%	-595.58%
Pretax Income	-$18.68M	-$63.75M	-$99.35M
YoY Change	267.57%	700.95%	183.09%
Income Tax	$215.0K	-$1.359M	$239.0K
% Of Pretax Income
Net Earnings	-$18.90M	-$64.39M	-$99.59M
YoY Change	238.98%	463.04%	166.75%
Net Earnings / Revenue	-34.61%	-112.45%	-42.69%
Basic Earnings Per Share	-$0.43		-$2.21
Diluted Earnings Per Share	-$0.43	-$1.32	-$2.21
COMMON SHARES
Basic Shares Outstanding	48.98M	48.96M	48.74M
Diluted Shares Outstanding	49.02M		48.74M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$448.5M	$456.8M	$456.8M
YoY Change	-14.17%	-12.72%	-12.72%
Cash & Equivalents	$49.66M	$46.35M	$5.367M
Short-Term Investments	$398.9M	$410.4M	$410.4M
Other Short-Term Assets	$10.89M	$10.08M	$10.08M
YoY Change	9.32%	8.16%	8.16%
Inventory	$25.02M	$26.21M	$26.21M
Prepaid Expenses
Receivables	$41.25M	$42.07M	$42.07M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$525.7M	$535.1M	$535.1M
YoY Change	-13.05%	-11.43%	-11.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$86.01M	$84.86M	$117.5M
YoY Change	20.7%	33.42%	29.88%
Goodwill	$107.6M	$108.4M
YoY Change	-29.04%	-28.27%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.432M	$2.336M	$2.336M
YoY Change	12.85%	146.67%	18.94%
Total Long-Term Assets	$417.1M	$422.6M	$422.6M
YoY Change	-5.94%	-2.75%	-2.75%
TOTAL ASSETS
Total Short-Term Assets	$525.7M	$535.1M	$535.1M
Total Long-Term Assets	$417.1M	$422.6M	$422.6M
Total Assets	$942.8M	$957.7M	$957.7M
YoY Change	-10.04%	-7.8%	-7.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$27.38M	$27.00M	$27.00M
YoY Change	5.86%	-3.75%	-3.75%
Accrued Expenses	$19.42M	$16.78M	$16.78M
YoY Change	33.56%	37.79%	37.79%
Deferred Revenue	$1.777M	$1.308M
YoY Change	76.11%	197.95%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$411.0K	$435.0K	$435.0K
YoY Change	573.77%	625.0%	625.0%
Total Short-Term Liabilities	$48.98M	$45.61M	$45.61M
YoY Change	17.79%	11.65%	11.65%
LONG-TERM LIABILITIES
Long-Term Debt	$381.4M	$380.8M	$380.8M
YoY Change	-6.51%	-6.49%	-6.49%
Other Long-Term Liabilities	$312.0K	$601.0K	$39.45M
YoY Change	-15.22%	33.26%	32.18%
Total Long-Term Liabilities	$312.0K	$601.0K	$420.3M
YoY Change	-15.22%	33.26%	-3.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$48.98M	$45.61M	$45.61M
Total Long-Term Liabilities	$312.0K	$601.0K	$420.3M
Total Liabilities	$470.7M	$468.7M	$468.7M
YoY Change	-3.47%	-2.94%	-2.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$661.3M	-$642.4M
YoY Change	20.59%	18.35%
Common Stock	$49.00K	$49.00K
YoY Change	-100.0%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$472.2M	$489.0M	$489.0M
YoY Change
Total Liabilities & Shareholders Equity	$942.8M	$957.7M	$957.7M
YoY Change	-10.04%	-7.8%	-7.8%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$18.90M	-$64.39M	-$99.59M
YoY Change	238.98%	463.04%	166.75%
Depreciation, Depletion And Amortization	$7.469M	$7.449M	$27.49M
YoY Change	16.63%	21.44%	20.74%
Cash From Operating Activities	-$3.265M	$2.482M	-$757.0K
YoY Change	-217.7%	-32.07%	-59.1%
INVESTING ACTIVITIES
Capital Expenditures	$4.006M	$12.24M	$38.79M
YoY Change	-58.14%	44.64%	75.44%
Acquisitions			$7.341M
YoY Change			12.01%
Other Investing Activities	$11.21M	-$2.518M	$80.95M
YoY Change	27.03%	-116.15%	-328.12%
Cash From Investing Activities	$6.445M	-$14.76M	$36.05M
YoY Change	-566.02%	-307.19%	-160.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	512.0K	-126.0K	-23.80M
YoY Change	621.13%	-97.63%	-39.25%
NET CHANGE
Cash From Operating Activities	-3.265M	2.482M	-757.0K
Cash From Investing Activities	6.445M	-14.76M	36.05M
Cash From Financing Activities	512.0K	-126.0K	-23.80M
Net Change In Cash	3.317M	-12.40M	9.751M
YoY Change	70.72%	-326.68%	-109.51%
FREE CASH FLOW
Cash From Operating Activities	-$3.265M	$2.482M	-$757.0K
Capital Expenditures	$4.006M	$12.24M	$38.79M
Free Cash Flow	-$7.271M	-$9.760M	-$39.54M
YoY Change	7.01%	102.91%	65.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001124524
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48987295
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45927591
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48334280
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48971026
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-34632
CY2023	dei	Entity Registrant Name EntityRegistrantName	CRYOPORT, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-0313393
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	112 Westwood Place
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 350
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Brentwood
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37027
CY2023	dei	City Area Code CityAreaCode	949
CY2023	dei	Local Phone Number LocalPhoneNumber	470-2300
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2023	dei	Trading Symbol TradingSymbol	CYRX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	500000000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48977476
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	Nashville, Tennessee
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Irvine, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46346000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36595000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	410409000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	486728000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42074000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	43858000
CY2023Q4	us-gaap	Inventory Net InventoryNet	26206000
CY2022Q4	us-gaap	Inventory Net InventoryNet	27678000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10077000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9317000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	535112000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	604176000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84858000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	63603000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32653000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26877000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	194382000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	191009000
CY2023Q4	us-gaap	Goodwill Goodwill	108403000
CY2022Q4	us-gaap	Goodwill Goodwill	151117000
CY2023Q4	us-gaap	Deposits Assets DepositsAssets	1680000
CY2022Q4	us-gaap	Deposits Assets DepositsAssets	1017000
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	656000
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	947000
CY2023Q4	us-gaap	Assets Assets	957744000
CY2022Q4	us-gaap	Assets Assets	1038746000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	26995000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	28046000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11409000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8458000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1308000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	439000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5371000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3720000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	286000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	128000
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	149000
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	60000
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	92000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45610000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40851000
CY2023Q4	cyrx	Convertible Subordinated Debt Discount ConvertibleSubordinatedDebtDiscount	7000000.0
CY2022Q4	cyrx	Convertible Subordinated Debt Discount ConvertibleSubordinatedDebtDiscount	10100000
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	378553000
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	406708000
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1335000
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	355000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29355000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24721000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	954000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	216000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2816000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4929000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	601000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	451000
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	9497000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4677000
CY2023Q4	us-gaap	Liabilities Liabilities	468721000
CY2022Q4	us-gaap	Liabilities Liabilities	482908000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48971026
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48334280
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	49000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	48000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1131183000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1114896000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-642419000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-542832000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-26065000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-34549000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	489023000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	555838000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	957744000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1038746000
CY2023	us-gaap	Revenues Revenues	233255000
CY2022	us-gaap	Revenues Revenues	237277000
CY2021	us-gaap	Revenues Revenues	222608000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	133923000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	133404000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	126031000
CY2023	us-gaap	Gross Profit GrossProfit	99332000
CY2022	us-gaap	Gross Profit GrossProfit	103873000
CY2021	us-gaap	Gross Profit GrossProfit	96577000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	146880000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	120055000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	97563000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18040000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15722000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16843000
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	49569000
CY2023	us-gaap	Operating Expenses OperatingExpenses	214489000
CY2022	us-gaap	Operating Expenses OperatingExpenses	135777000
CY2021	us-gaap	Operating Expenses OperatingExpenses	114406000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-115157000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-31904000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-17829000
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	10577000
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	8474000
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	3253000
CY2023	us-gaap	Interest Expense InterestExpense	5503000
CY2022	us-gaap	Interest Expense InterestExpense	6142000
CY2021	us-gaap	Interest Expense InterestExpense	4689000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	5679000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-251754000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5056000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5522000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2823000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15809000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3190000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-256013000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-99348000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35094000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-273842000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	239000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2239000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1686000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-99587000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37333000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-275528000
CY2023	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	8000000
CY2022	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	8000000
CY2021	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	8196000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-107587000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45333000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-283724000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.21
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.21
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.18
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.18
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48737377
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48737377
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48987295
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48987295
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45927591
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45927591
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-99587000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37333000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-275528000
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	6742000
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-23439000
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-3958000
CY2023	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-3008000
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	46000
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	27000
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1266000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9821000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2634000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	8484000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-33306000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6619000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-91103000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-70639000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-282147000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	382698000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-275528000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6619000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15334000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11000
CY2021	cyrx	Adjustments To Additional Paid In Capital Conversion Costs AdjustmentsToAdditionalPaidInCapitalConversionCosts	-1800000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	269825000
CY2021	cyrx	Issuance Of Common Stock In Direct Placement Net IssuanceOfCommonStockInDirectPlacementNet	248911000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8996000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	641828000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37333000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-33306000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20082000
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	479000
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	37960000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2048000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	555838000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-99587000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	8484000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22808000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1480000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	489023000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-99587000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37333000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-275528000
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	49569000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27487000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22765000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20247000
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2526000
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2581000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1236000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	5103000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	3645000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	3367000
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	1308000
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-11406000
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1386000
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-67000
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-102000
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-81000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22808000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20082000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15345000
CY2023	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-954000
CY2022	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-800000
CY2021	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-542000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	5679000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-251754000
CY2023	cyrx	Gain Loss On Insurance Settlement GainLossOnInsuranceSettlement	2642000
CY2022	cyrx	Gain Loss On Insurance Settlement GainLossOnInsuranceSettlement	4815000
CY2023	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	822000
CY2022	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	234000
CY2021	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	26000
CY2022	cyrx	Excess And Obsolete Inventory ExcessAndObsoleteInventory	651000
CY2023	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	1212000
CY2022	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	9883000
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-890000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	216000
CY2023	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-3673000
CY2022	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	4137000
CY2021	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	7270000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1508000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14204000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5979000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	103000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1598000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3056000
CY2023	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	663000
CY2022	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	60000
CY2021	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-211000
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4595000
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2884000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1569000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3076000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2805000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2766000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6483000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-398000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2522000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	842000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-530000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	102000
CY2023	cyrx	Net Deferred Tax Expense Income NetDeferredTaxExpenseIncome	-1979000
CY2022	cyrx	Net Deferred Tax Expense Income NetDeferredTaxExpenseIncome	-411000
CY2021	cyrx	Net Deferred Tax Expense Income NetDeferredTaxExpenseIncome	231000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-757000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1851000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8126000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	38785000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22107000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23882000
CY2023	cyrx	Payments For Proceeds From Insurance Proceeds For Loss From Fixed Assets PaymentsForProceedsFromInsuranceProceedsForLossFromFixedAssets	-976000
CY2022	cyrx	Payments For Proceeds From Insurance Proceeds For Loss From Fixed Assets PaymentsForProceedsFromInsuranceProceedsForLossFromFixedAssets	-3000000
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	42677000
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	163788000
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	482707000
CY2023	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	129987000
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	131858000
CY2021	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	44000000
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	871000
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	614000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	255000
CY2023	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	5244000
CY2022	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	1476000
CY2021	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	870000
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	7341000
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	6554000
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	5540000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	36045000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-59681000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-469254000
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1478000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2048000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	8995000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	37960000
CY2023	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	25003000
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	248911000
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	269825000
CY2023	cyrx	Repayment Of Finance Lease Liabilities RepaymentOfFinanceLeaseLiabilities	202000
CY2022	cyrx	Repayment Of Finance Lease Liabilities RepaymentOfFinanceLeaseLiabilities	82000
CY2021	cyrx	Repayment Of Finance Lease Liabilities RepaymentOfFinanceLeaseLiabilities	60000
CY2023	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-71000
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-3180000
CY2021	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-3397000
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	40068000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-23798000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-39174000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	564342000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1739000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1800000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-986000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9751000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-102506000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	102228000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36595000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139101000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36873000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46346000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36595000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139101000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	3399000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	3628000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	3297000
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	1462000
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	1979000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	1315000
CY2023	cyrx	Non Cash Net Unrealized Gain Loss On Available For Sale Securities NonCashNetUnrealizedGainLossOnAvailableForSaleSecurities	6742000
CY2022	cyrx	Non Cash Net Unrealized Gain Loss On Available For Sale Securities NonCashNetUnrealizedGainLossOnAvailableForSaleSecurities	23439000
CY2021	cyrx	Non Cash Net Unrealized Gain Loss On Available For Sale Securities NonCashNetUnrealizedGainLossOnAvailableForSaleSecurities	3958000
CY2023	cyrx	Reclassification Of Realized Gain On Available For Sale Debt Securities To Earnings ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings	-3008000
CY2022	cyrx	Reclassification Of Realized Gain On Available For Sale Debt Securities To Earnings ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings	46000
CY2021	cyrx	Reclassification Of Realized Gain On Available For Sale Debt Securities To Earnings ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings	27000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	442000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1003000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1412000
CY2023	cyrx	Paid In Kind Preferred Stock Dividend Including Beneficial Conversion Feature PaidInKindPreferredStockDividendIncludingBeneficialConversionFeature	8000000
CY2022	cyrx	Paid In Kind Preferred Stock Dividend Including Beneficial Conversion Feature PaidInKindPreferredStockDividendIncludingBeneficialConversionFeature	8000000
CY2021	cyrx	Paid In Kind Preferred Stock Dividend Including Beneficial Conversion Feature PaidInKindPreferredStockDividendIncludingBeneficialConversionFeature	8196000
CY2023	cyrx	Intangible Assets Included In Property And Equipment IntangibleAssetsIncludedInPropertyAndEquipment	8710000
CY2023	cyrx	Purchase Of Equipment Through Capital Lease Obligation PurchaseOfEquipmentThroughCapitalLeaseObligation	1112000
CY2023	cyrx	Operating Lease Right Of Use Assets And Lease Liabilities OperatingLeaseRightOfUseAssetsAndLeaseLiabilities	11109000
CY2022	cyrx	Operating Lease Right Of Use Assets And Lease Liabilities OperatingLeaseRightOfUseAssetsAndLeaseLiabilities	12384000
CY2021	cyrx	Operating Lease Right Of Use Assets And Lease Liabilities OperatingLeaseRightOfUseAssetsAndLeaseLiabilities	10175000
CY2021	cyrx	Common Stock Issued For Conversion Of Debt And Accrued Interest CommonStockIssuedForConversionOfDebtAndAccruedInterest	765000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1. Nature of the Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cryoport is a leading global provider of innovative products and services supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Our mission is to enable the future of medicine for a new era of life sciences. With over 50 strategic locations covering the Americas, EMEA (Europe, the Middle East and Africa) and APAC (Asia Pacific), Cryoport's global platform provides mission-critical bio-logistics, bio-storage, bio-processing, and cryogenic systems to over 3,000 customers worldwide. Our platform of solutions and services, together with our global team of over 1,100 dedicated colleagues, delivers a unique combination of innovative supply chain technologies and services through our industry-leading brands, including Cryoport Systems, MVE Biological Solutions, CRYOPDP, and CRYOGENE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”</p>
CY2023	cyrx	Number Of Strategic Locations NumberOfStrategicLocations	50
CY2023	cyrx	Number Of Customers NumberOfCustomers	3000
CY2023	cyrx	Number Of Colleagues NumberOfColleagues	1100
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	cyrx	Maturity Period Of Highly Liquid Investments MaturityPeriodOfHighlyLiquidInvestments	P90D
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the fair value of short-term investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates, including valuation multiples utilized in the market approach used in impairment assessments, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, contingent consideration liability, equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future events and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”). Primarily all of our cash, cash equivalents and short-term investments at December 31, 2023 were in excess of amounts insured by the FDIC and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly rated instruments, and limit investing in long-term maturity instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investment policy requires that purchased instruments in marketable securities may only be in highly rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.</p>
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P5Y
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q2	cyrx	Statutory Credit Usage Limit For Research And Development For Tax Relief StatutoryCreditUsageLimitForResearchAndDevelopmentForTaxRelief	5000000
CY2021Q1	cyrx	Executive Compensation Limit ExecutiveCompensationLimit	1000000
CY2023	us-gaap	Revenue Practical Expedient Remaining Performance Obligation RevenuePracticalExpedientRemainingPerformanceObligation	true
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	700000
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1300000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	400000
CY2023	cyrx	Contract With Customer Liability Revenue Recognized Excluding Opening Balance ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance	2100000
CY2022	cyrx	Contract With Customer Liability Revenue Recognized Excluding Opening Balance ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance	1400000
CY2021	cyrx	Contract With Customer Liability Revenue Recognized Excluding Opening Balance ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance	300000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2000000.0
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1300000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1275000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1220000
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	812000
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	100000
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	95000
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	45000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1992000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1275000
CY2023	us-gaap	Revenues Revenues	233255000
CY2022	us-gaap	Revenues Revenues	237277000
CY2021	us-gaap	Revenues Revenues	222608000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37333000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-275528000
CY2023	us-gaap	Revenues Revenues	233255000
CY2022	us-gaap	Revenues Revenues	237277000
CY2021	us-gaap	Revenues Revenues	222608000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-99587000
CY2023	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	8000000
CY2022	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	8000000
CY2021	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	8196000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-107587000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45333000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-283724000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48737377
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48737377
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48987295
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48987295
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45927591
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45927591
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.21
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.21
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.18
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.18
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13214338
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14609804
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15290040
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1300000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-9800000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2600000
CY2023Q4	cyrx	Business Combination Consideration Upfront Fees BusinessCombinationConsiderationUpfrontFees	1800000
CY2023Q4	cyrx	Business Combination Consideration Upfront Fees BusinessCombinationConsiderationUpfrontFees	1900000
CY2023Q4	us-gaap	Cash Cash	40979000
CY2022Q4	us-gaap	Cash Cash	34752000
CY2023Q4	us-gaap	Cash Cash	40979000
CY2022Q4	us-gaap	Cash Cash	34752000
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	5367000
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1843000
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	5367000
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1843000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46346000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36595000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46346000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36595000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	410409000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	486728000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	410409000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	486728000
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	456755000
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	523323000
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	456755000
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	523323000
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	302581000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6764000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	22000
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	309323000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	101252000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	103802000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	201329000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	205521000
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	302581000
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	309323000
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	410390000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1248000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	24687000
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	386951000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	129568000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	126776000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	280822000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	260175000
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	410390000
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	386951000
CY2023Q4	cyrx	Available For Sale Securities Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesUnrealizedLossPositionLessThanTwelveMonthsFairValue	53726000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	22000
CY2023Q4	cyrx	Available For Sale Securities Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesUnrealizedLossPositionTwelveMonthsOrLongerFairValue	255597000
CY2023Q4	cyrx	Available For Sale Securities Unrealized Loss Position Fair Value AvailableForSaleSecuritiesUnrealizedLossPositionFairValue	309323000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	22000
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-100000
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-100000
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-80000.00
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	101800000
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	99800000
CY2023	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-3764000
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-11406000
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-1386000
CY2023	cyrx	Equity Securities Realized Gain Loss Sold EquitySecuritiesRealizedGainLossSold	5072000
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1308000
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-11406000
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-1386000
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	15335000
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	18287000
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1375000
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	895000
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	9496000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	8496000
CY2023Q4	us-gaap	Inventory Net InventoryNet	26206000
CY2022Q4	us-gaap	Inventory Net InventoryNet	27678000
CY2023Q4	cyrx	Cryogenic Shippers And Data Loggers CryogenicShippersAndDataLoggers	14237000
CY2022Q4	cyrx	Cryogenic Shippers And Data Loggers CryogenicShippersAndDataLoggers	11373000
CY2023Q4	cyrx	Freezers Gross FreezersGross	8934000
CY2022Q4	cyrx	Freezers Gross FreezersGross	7320000
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	6351000
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	3760000
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	4908000
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	2824000
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	19760000
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	16492000
CY2023Q4	cyrx	Trucks And Autos Gross TrucksAndAutosGross	1878000
CY2022Q4	cyrx	Trucks And Autos Gross TrucksAndAutosGross	853000
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	33688000
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	27083000
CY2023Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	6652000
CY2022Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	4473000
CY2023Q4	us-gaap	Land Land	813000
CY2022Q4	us-gaap	Land Land	813000
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	24224000
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	15947000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	121445000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	90938000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	36588000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	27335000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84858000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	63603000
CY2023	us-gaap	Depreciation Depreciation	11200000
CY2022	us-gaap	Depreciation Depreciation	7700000
CY2021	us-gaap	Depreciation Depreciation	5800000
CY2023Q4	cyrx	Leases Equipment Under Finance Leases Amount LeasesEquipmentUnderFinanceLeasesAmount	1200000
CY2022Q4	cyrx	Leases Equipment Under Finance Leases Amount LeasesEquipmentUnderFinanceLeasesAmount	500000
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	200000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	200000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84858000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	63603000
CY2022Q4	us-gaap	Goodwill Goodwill	151117000
CY2021Q4	us-gaap	Goodwill Goodwill	146954000
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-284000
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-5391000
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	49569000
CY2023Q4	us-gaap	Goodwill Goodwill	108403000
CY2022Q4	us-gaap	Goodwill Goodwill	151117000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	247250000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	52868000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	194382000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	231344000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	40335000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	191009000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16300000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15100000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14400000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	16897000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	14878000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	14590000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	14245000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	13199000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	70927000
CY2023Q4	cyrx	Future Amortization Of Finite Lived Intangible Assets FutureAmortizationOfFiniteLivedIntangibleAssets	144736000
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8639000
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6007000
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2770000
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2451000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11409000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8458000
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	202000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	70000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	58000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	11109000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	12384000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	10175000
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	6976000
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	10136000
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	378553000
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	406708000
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3380000
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3496000
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1005000
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2526000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2537000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3419000
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	5906000
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	6033000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	4424000
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	117.59
CY2023Q4	us-gaap	Long Term Debt Term LongTermDebtTerm	P5Y
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	1090000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	259000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y4M24D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.087
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	7294000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	5505000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	4556000
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	219000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	79000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	61000
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	61000
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	12000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	8000
CY2023	cyrx	Finance Lease Cost FinanceLeaseCost	280000
CY2022	cyrx	Finance Lease Cost FinanceLeaseCost	91000
CY2021	cyrx	Finance Lease Cost FinanceLeaseCost	69000
CY2023	us-gaap	Lease Cost LeaseCost	7574000
CY2022	us-gaap	Lease Cost LeaseCost	5596000
CY2021	us-gaap	Lease Cost LeaseCost	4625000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	6720000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	4733000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	3993000
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	263000
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	82000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	65000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3707000
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.095
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.084
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.078
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8063000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	374000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6929000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	370000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5741000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	343000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4962000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	228000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	122000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	27076000
CY2023Q4	cyrx	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	26000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	56478000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1463000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	21752000
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	223000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	34726000
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1240000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5371000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	286000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29355000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	954000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	34726000
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1240000
CY2022Q1	cyrx	Estimated Revenue Impact Due To Catastrophes EstimatedRevenueImpactDueToCatastrophes	9400000
CY2023	cyrx	Proceeds From Insurance Settlement ProceedsFromInsuranceSettlement	15100000
CY2023Q1	cyrx	Proceeds From Insurance Settlement ProceedsFromInsuranceSettlement	2200000
CY2023Q4	cyrx	Gain Loss On Insurance Settlement Related To Business Interruption GainLossOnInsuranceSettlementRelatedToBusinessInterruption	2600000
CY2022Q4	cyrx	Gain Loss On Insurance Settlement Related To Business Interruption GainLossOnInsuranceSettlementRelatedToBusinessInterruption	4200000
CY2022Q4	cyrx	Gain Loss On Insurance Settlement For Reimbursement Of Property And Equipment GainLossOnInsuranceSettlementForReimbursementOfPropertyAndEquipment	600000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	100000000.0
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1604994
CY2022	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	23.63
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	37900000
CY2023	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0
CY2023	us-gaap	Dividends Paidinkind DividendsPaidinkind	8000000.0
CY2022	us-gaap	Dividends Paidinkind DividendsPaidinkind	8000000.0
CY2021	us-gaap	Dividends Paidinkind DividendsPaidinkind	8200000
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	57500000
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17952421
CY2023	cyrx	Number Of Stock Incentive Plans NumberOfStockIncentivePlans	5
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.035
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.044
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.021
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.037
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0047
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0118
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.699
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.800
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.675
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.786
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.644
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.808
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	22808000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	20082000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	15345000
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6700000
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5200000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-99348000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35094000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-273842000
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	73000
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	70000
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	112000
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2263000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2634000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1783000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2336000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2704000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1895000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-278000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7712000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-11646000
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-423000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-191000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1564000
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1396000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1545000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1126000
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	8983000
CY2021	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	14127000
CY2023	cyrx	Deferred Income Tax Expense Benefit Total DeferredIncomeTaxExpenseBenefitTotal	-2097000
CY2022	cyrx	Deferred Income Tax Expense Benefit Total DeferredIncomeTaxExpenseBenefitTotal	-465000
CY2021	cyrx	Deferred Income Tax Expense Benefit Total DeferredIncomeTaxExpenseBenefitTotal	-209000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	239000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2239000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1686000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	53804000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40927000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5654000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4847000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	1850000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	4081000
CY2023Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	3918000
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	9365000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5224000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2724000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3761000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2046000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	806000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	860000
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3526000
CY2023Q4	cyrx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	5076000
CY2022Q4	cyrx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	4712000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	83619000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	69562000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	77194000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61700000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	6425000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7862000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	2779000
CY2023Q4	cyrx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	4674000
CY2022Q4	cyrx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	4382000
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2926000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	3906000
CY2023Q4	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	985000
CY2022Q4	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	777000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8585000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11844000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2160000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3982000
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	656000
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	947000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2816000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4929000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2160000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3982000
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-20863000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7370000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-57507000
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-277000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	296000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1222000
CY2021	cyrx	Income Tax Reconciliation Non Deductible Expense Loss On Debt Extinguishment IncomeTaxReconciliationNonDeductibleExpenseLossOnDebtExtinguishment	50817000
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1660000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1881000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-7543000
CY2023	cyrx	Effective Income Tax Rate Reconciliation Deemed Foreign Dividend Income EffectiveIncomeTaxRateReconciliationDeemedForeignDividendIncome	1874000
CY2021	cyrx	Effective Income Tax Rate Reconciliation Deemed Foreign Dividend Income EffectiveIncomeTaxRateReconciliationDeemedForeignDividendIncome	198000
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	793000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	590000
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-172000
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	352000
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	813000
CY2023	cyrx	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	20000
CY2022	cyrx	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	160000
CY2023	cyrx	Effective Income Tax Rate Reconciliation Executive Compensation Amount EffectiveIncomeTaxRateReconciliationExecutiveCompensationAmount	40000
CY2022	cyrx	Effective Income Tax Rate Reconciliation Executive Compensation Amount EffectiveIncomeTaxRateReconciliationExecutiveCompensationAmount	83000
CY2021	cyrx	Effective Income Tax Rate Reconciliation Executive Compensation Amount EffectiveIncomeTaxRateReconciliationExecutiveCompensationAmount	1894000
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-471000
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-113000
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	105000
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	3614000
CY2023	cyrx	Effective Income Tax Rate Reconciliation Contingencies EffectiveIncomeTaxRateReconciliationContingencies	-613000
CY2022	cyrx	Effective Income Tax Rate Reconciliation Contingencies EffectiveIncomeTaxRateReconciliationContingencies	-1443000
CY2021	cyrx	Effective Income Tax Rate Reconciliation Contingencies EffectiveIncomeTaxRateReconciliationContingencies	8000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	16220000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8983000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14123000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	239000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2239000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1686000

Files In Submission

Name	View Source	Status
0001558370-24-003128-index-headers.html	Edgar Link	pending
0001558370-24-003128-index.html	Edgar Link	pending
0001558370-24-003128.txt	Edgar Link	pending
0001558370-24-003128-xbrl.zip	Edgar Link	pending
cyrx-20231231.xsd	Edgar Link	pending
cyrx-20231231x10k.htm	Edgar Link	pending
cyrx-20231231x10k004.jpg	Edgar Link	pending
cyrx-20231231x10k008.jpg	Edgar Link	pending
cyrx-20231231x10k009.jpg	Edgar Link	pending
cyrx-20231231x10k010.jpg	Edgar Link	pending
cyrx-20231231xex10d11.htm	Edgar Link	pending
cyrx-20231231xex21.htm	Edgar Link	pending
cyrx-20231231xex23d1.htm	Edgar Link	pending
cyrx-20231231xex23d2.htm	Edgar Link	pending
cyrx-20231231xex31d1.htm	Edgar Link	pending
cyrx-20231231xex31d2.htm	Edgar Link	pending
cyrx-20231231xex32d1.htm	Edgar Link	pending
cyrx-20231231xex32d2.htm	Edgar Link	pending
cyrx-20231231xex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
cyrx-20231231_pre.xml	Edgar Link	unprocessable
cyrx-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cyrx-20231231x10k_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cyrx-20231231_def.xml	Edgar Link	unprocessable
cyrx-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYRX
Cryoport, Inc. Stock $cyrx

2024 Q1 Form 10-K Financial Statement

#000155837024003128 Filed on March 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX Cryoport, Inc. Stock $cyrx

2024 Q1 Form 10-K Financial Statement

#000155837024003128 Filed on March 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX
Cryoport, Inc. Stock $cyrx